Neuphoria Therapeutics Inc.
We are a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. Neuphoria is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the 7 nicotinic acetylcholine ("ACh") receptor ("a7 receptor") for the acute, as needed treatment of social an…
$3.30
-$0.01 (-0.30%)
EOD Oct 16, 2026
The business is unprofitable at the operating level (-1401.09% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 92.5% YoY. Margins deteriorated 1393.9pp alongside, both lines moving the wrong way.
ROIC dropped from -4.84% to -59.45%, capital efficiency is deteriorating. Operating margin contracted 1393.9pp YoY, cost discipline may be slipping.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$1M
▼ -92.5% YoY
Net Income (TTM)
-$13M
▼ -3539.3% YoY
Op. Margin
-1401.09%
▼ -1393.9pp YoY
ROIC
-59.45%
▼ -54.6pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$12M
▼ -16095.4% YoY
Net Debt
-$20M
Net Cash Position
Cash & Equiv.
$20M
Continue Research
SourceComputed from the 10-Q filed 17 Sept 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 19 Sept 2026. How this is calculated.
Price from market data, last close as of 16 Oct 2026. Fiscal year ends Jun. Sector medians are approximate S&P 500 benchmarks and update periodically.
Is Neuphoria Therapeutics (NEUP) overvalued?
Neuphoria Therapeutics (NEUP)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Neuphoria Therapeutics scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is Neuphoria Therapeutics a high-quality business?+
Neuphoria Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 5 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -1,401.1% operating margin and a -59.5% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Neuphoria Therapeutics a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh NEUP's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.
Related stocks: Pharmaceutical Preparations
Spot a number that looks wrong?
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.